Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist - from mice to men

Theranostics

Volumn 4, Issue 4, 2014, Pages 412-419

  Wieser, Gesche ^a   Mansi, Rosalba ^a   Grosu, Anca L ^a   Schultze Seemann, Wolfgang ^a   Dumont Walter, Rebecca A ^a,b   Meyer, Philipp T ^a,c   Maecke, Helmut R ^a,c   Reubi, Jean Claude ^d   Weber, Wolfgang A ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bombesin; Gastrin releasing peptide receptor; PET CT; Prostate cancer

Indexed keywords

CB TE2A AR06 CU 64; COPPER 64; GASTRIN RELEASING PEPTIDE RECEPTOR; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSIMETRY; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STRUCTURE; DRUG TUMOR LEVEL; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROSTATE BIOPSY; PROSTATE CANCER; RADIOACTIVITY; TUMOR VOLUME;

BOMBESIN; GASTRIN RELEASING PEPTIDE RECEPTOR; PET/CT; PROSTATE CANCER.;

AGED; CONTRAST MEDIA; COORDINATION COMPLEXES; HUMANS; KIDNEY; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; PANCREAS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 84902465516     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7324     Document Type: Article

References (33)

1. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007; 243: 28-53.
2. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011; 59: 51-60.
3. Souvatzoglou M, Weirich G, Schwarzenboeck S, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011; 17: 3751-3759.
4. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008; 60: 1-42.
5. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999; 59: 1152-1159.
6. Bodei L, Ferrari M, Nunn A, et al. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging. 2007; 34 (Suppl 2): S221.
7. Schwartsmann G, DiLeone LP, Horowitz M, et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs. 2006; 24: 403-412.
8. Abiraj K, Mansi R, Tamma ML, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing Peptide receptor-positive tumors. J Nucl Med. 2011; 52: 1970-1978.
9. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009; 15: 5240-5249.
10. Shokeen M, Anderson C. Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET). Accounts of Chemical Research. 2009; 42: 832-841.
11. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002; 43: 92-96.
12. Jadvar H. Molecular Imaging of Prostate Cancer with PET. J Nucl Med. 2013; 54: 1685-1688.
13. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48: 56-63.
14. Nanni C, Schiavina R, Boschi S, et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013; 40 Suppl 1: S11-17.
15. Osborne JR, Green DA, Spratt DE, et al. A Prospective Pilot Study of 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. J Urol. 2013; [epub ahead of print].
16. Morris M, Pandit-Taskar N, Carrasquillo J, et al. Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2013; 31 (suppl 6).
17. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013; 40: 486-495.
18. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012; 53: 1883-1891.
19. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013.
20. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004; 45: 366-373.
21. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 2013; 40: 244-258.
22. Scher HI, Morris MJ, Larson S, Heller G. Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol. 2013; 10: 225-234.
23. Craft JM, De Silva RA, Lears KA, et al. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. Nucl Med Biol. 2012; 39: 609-616.
24. Chen X, Park R, Hou Y, et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004; 45: 1390-1397.
25. Prasanphanich AF, Nanda PK, Rold TL, et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A. 2007; 104: 12462-12467.
26. Van de Wiele C, Dumont F, Dierckx RA, et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001; 42: 1722-1727.
27. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006; 103: 16436-16441.
28. Schroeder RP, Muller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010; 37: 1386-1396.
29. Kahkonen E, Jambor I, Kemppainen J, et al. In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548. Clin Cancer Res. 2013; 19: 5434-5443.
30. Maddalena ME, Fox J, Chen J, et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009; 50: 2017-2024.
31. Wild D, Frischknecht M, Zhang H, et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 2011; 71: 1009-1018.
32. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002; 8: 1139-1146.
33. Fleischmann A, Waser B, Reubi JC. Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol. 2007; 29: 421-433.